The Sperling Prostate Center is pleased to join seven academic centers in announcing the results of our national clinical trial of a novel focal prostate cancer treatment. keep reading
Chronic inflammation can occur in the body without your even being aware of it—and it's estimated to be the cause of up to 20% of all cancers. How to minimize this potentially deadly condition? keep reading
Prostate enlargement unpleasantly restricts urine flow...but the very same enlargement may also cause BPH to restrict prostate cancer tumor growth... keep reading
A prominent urologist wrote an articulate article on how the U.S. Preventive Services Task Force made a recommendation against broad PSA screening based on an oversimplification of a complex issue. He made an eloquent declaration on several ways in which urologists are “embracing strategies to preserve, or even further decrease, prostate cancer mortality while minimizing keep reading
It’s always reassuring to receive affirmation, especially when offering a leading edge medical program to prostate cancer patients. Such was the case for us at the Sperling Prostate Center with the December, 2015 publication of a UCLA Medical Center study on the value-added of multiparametric MRI during Active Surveillance (AS). The authoritative Journal of Urology keep reading
Here’s a little quiz: Which whole gland therapy for prostate cancer has the highest risk of recurrence? Radical prostatectomy Radiation therapy Cryotherapy of the whole gland HIFU of the whole gland If you answered radiation, you are correct. According to a recent article, the rate of prostate cancer coming back after conventional external beam radiation keep reading
We know that the use of Active Surveillance (AS) as a way to hold off on prostate cancer (PCa) treatment is on the rise. Concerns about overtreatment, such as doing a prostatectomy on a patient who only has a small Gleason 3+3 tumor, stem from two recognized realities: Insignificant PCa may be slow-growing (indolent) and keep reading
Until about 10 years ago, conventional prostate cancer treatments were based on the assumption that prostate cancer is a multifocal disease. All conventional treatment modalities (surgery, radiotherapy, and thermal ablation) were “radical” because they were directed at the removal or destruction of the whole gland. Such treatments, however, put urinary and sexual function at risk, keep reading
The strategy of using active surveillance (AS) is increasingly recommended to low-risk prostate cancer (PCa) patients as a way to avoid or delay overtreatment. This is a new way of thinking; before the New Millennium, PCa was assumed to be multi-focal and most men with more than 10 years of life expectancy were hurried into keep reading
At the Sperling Prostate Center, we believe family history matters, and patients who have a hereditary history of any kind of cancer, especially first degree relatives deserve special counseling. keep reading
The vast majority of published literature on prostate cancer (PCa), and also patient advocacy websites, often seem to overlook the needs of minority populations. Differences such as genetic vulnerability (suggested by higher incidence and death rates for African American men) or ethnic differences in male identity and how men relate to their bodies are not keep reading
I recently posted a summary of an Italian study showing that MRI (mpMRI) was superior to other prostate cancer tests in terms of predicting the need for a repeat biopsy after a previously negative result. mpMRI is able to show if there is a need for another biopsy. This is happy news for patients, who dread having keep reading
I have written on the importance of a healthy lifestyle, especially diet and nutrition, which is correlated with preventing prostate cancer (PCa) and other diseases. (NOTE: You can read some of my related blogs from links at the end of this one.) I came across a new multi-center Italian study that addresses the question: does keep reading